Aakaar adds five franchises to its medical aesthetics portfolio

Aakaar® is broadening its medical-aesthetics portfolio through five franchises spanning botulinum toxin, hyaluronic acid fillers, exosomes and digital dermatology imaging. The company’s 2026 presentation identifies VM Corp. as a three-product range for hair, skin and body, while its launch record lists Letybo and Xomage in 2026 and FotoFinder in 2025.

What are Aakaar’s five aesthetics franchises?

Aakaar identifies Letybo, Sayphar, VM Corp., Xomage and FotoFinder as five franchises that cover injectable treatments, regenerative products and dermatology diagnostics. Letybo is a neuromodulator, Sayphar is a dermal filler, VM Corp. is a regenerative suite, Xomage is a plant-exosome platform, and FotoFinder provides digital dermoscopy technology.

Letybo is a Korean botulinum toxin with United States Food and Drug Administration, or US FDA, approval, according to the presentation. Aakaar says Letybo replaces Medytox/SIAX in its portfolio; management describes the new franchise as cleaner and stronger. The 2026 launch list places Letybo alongside DermLite DL5 Plus and Xomage.

Sayphar is an Austrian hyaluronic acid, or HA, filler with US FDA approval. Aakaar says it competes in the premium segment with Juvederm and Restylane. The historical launch table separately records saypha volume, saypha filler and saypha rich in 2021, followed by saypha volume plus in 2022, but does not explain the relationship between Sayphar and those earlier names.

VM Corp. is an Italian exosome range comprising three products for hair, skin and body, while Xomage is a Korean plant-exosome platform. Management calls Xomage a first-mover exclusive and describes plant exosomes as the next frontier of biologic aesthetics. The presentation does not give a launch year for VM Corp., although it lists EXOLUXE in 2024 and Xomage in 2026.

How does FotoFinder change Aakaar’s product mix?

FotoFinder adds diagnostic imaging technology to Aakaar’s offering rather than an injectable or regenerative treatment. The presentation describes FotoFinder as a pioneer in Automated Total Body Mapping, or ATBM, and digital dermoscopy for early skin-cancer detection and artificial intelligence, or AI, powered dermatology diagnostics.

Aakaar’s 2025 product list includes FotoFinder and DermLite DL5, followed by DermLite DL5 Plus in 2026. This sequence indicates that the recent catalogue has added imaging and dermoscopy alongside treatments such as Letybo, rather than remaining limited to devices, consumables and aesthetic-treatment products.

FotoFinder has a different stated role from Letybo and Sayphar: its platform is used for skin imaging and dermatology diagnostics, while Letybo is a neuromodulator and Sayphar is an HA filler. Aakaar provides no revenue, installed-base or customer figures for FotoFinder, so its disclosed contribution is limited to the technology’s stated applications and its 2025 listing.

The product record also shows that Aakaar introduced DermLite DL5 in 2025 before the DL5 Plus version in 2026. Together with FotoFinder’s ATBM capability, those entries place digital dermoscopy and imaging within the company’s more recent additions, alongside the five-franchise strategy outlined in the 2026 presentation.

When do the five franchises appear in Aakaar’s launch record?

Aakaar’s launch record lists FotoFinder in 2025 and Letybo and Xomage in 2026, while related saypha products were listed in 2021 and 2022. The table covers products introduced from 2010 through 2026 but does not specify a launch year for VM Corp. or reconcile Sayphar with the earlier saypha entries.

The mix changed between 2021-22 and 2025-26. The earlier entries in the table were saypha filler variants, whereas the latest two years include FotoFinder imaging, a botulinum toxin through Letybo, plant exosomes through Xomage and an updated DermLite device. Aakaar groups the five franchises under its stated strategy of building an aesthetics ecosystem.

The longer launch history includes hyaluronic acid in 2013, aqua lift in 2014, BLACK PEEL in 2015 and Regenera Activa AMT in 2023. That 2010-2026 record shows additions across skincare, hair, fillers and devices; the 2025-26 additions bring diagnostic imaging, toxin and plant-exosome categories into the disclosed mix. The presentation gives no sales target or revenue forecast for any of the five franchises.

How does Aakaar plan to support doctor adoption?

Aakaar plans to support adoption through training and certification for practising dermatologists and students in dermal fillers, threads and toxins. The company reports more than 75 programmes conducted, more than 574 people trained and more than 44 ventures, although the presentation does not define the period or measure represented by “ventured.”

The training programme directly covers the toxin and filler categories represented by Letybo and Sayphar. Aakaar says workshops are conducted under experienced doctors and practitioners, with stated outcomes including awareness of medical aesthetics, product use at the outset of doctors’ practices, organic promotion and sample distribution across audiences.

Aakaar also reports direct coverage and telecalling of more than 12,000 doctors across India to offer products and devices. It says it participated in more than 20 international, national and local conferences, including AMWC, IMCAS, DERMACON, CDSI, Aesthetics and AOMSI. These activities cover the wider portfolio rather than being reported separately for the five franchises.

The company says its Masterclass in Contouring Aesthetics, or MICA, is conducted across Tier-I and Tier-II cities. A trichology workshop began in FY 2025-26, which corresponds with VM Corp.’s stated hair application. Aakaar does not disclose attendance, product conversion or sales data from MICA, the trichology workshop or the 75-plus training programmes.

Conclusion

Aakaar’s five-franchise strategy combines treatment categories and diagnostic technology in one portfolio. Letybo adds a botulinum toxin, Sayphar adds an HA filler, VM Corp. covers three regenerative applications, Xomage provides plant exosomes and FotoFinder brings ATBM and digital dermoscopy. Compared with filler-focused saypha entries in 2021-22, the 2025-26 additions broaden the recorded product mix.

What to watch next is execution through Aakaar’s disclosed doctor-engagement plan: more than 75 training programmes, outreach to more than 12,000 doctors and MICA workshops in Tier-I and Tier-II cities. The presentation does not disclose a VM Corp. launch date, franchise-level commercial metrics or a revenue outlook, leaving adoption and financial contribution unresolved in future disclosures.